Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Celgene President Thomas Daniel said the expansion reflects 'substantive progress and unique advantages of Sutro's platform' supporting the company's…
The expanded Celgene-Sutro cancer antibody and ADC partnership grows to more than $1 billion in potential payments, building on the companies' December…
By 2017 Celgene and Sutro refocused the 2014 IO collaboration onto four programs (incl. a BCMA-targeting ADC); the buyout option ultimately lapsed, freeing…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Celgene paid Sutro $95M upfront (including equity) plus up to $90M in research-term payments for multi-year rights to discover bispecific antibodies and ADCs against immuno-oncology targets including PD-1/PD-L1 using Sutro's cell-free XpressCF platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Sutro Biopharma, Inc. (this deal) | 2014 | $185M | — |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
← Browse all deals · How we score deals
More: 2014 deals · Celgene Corporation deals · Oncology deals